title: How does HAART lead to the resolution of Kaposi's sarcoma?
authors.affiliation: Department of Immunology, The Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK. j.stebbing@ic.ac.uk
authors.forename: Justin
authors.initials: J
authors.lastname: Stebbing
authors.forename: Simon
authors.initials: S
authors.lastname: Portsmouth
authors.forename: Brian
authors.initials: B
authors.lastname: Gazzard
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D016207:Cytokines / Q000037:antagonists & inhibitors; D015658:HIV Infections / Q000150:complications / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000276:immunology
chemical_list: D020533:Angiogenesis Inhibitors; D016207:Cytokines